Literature DB >> 3704105

Problems of anticoagulation with warfarin in hyperthyroidism.

H A Kellett, J S Sawers, F E Boulton, S Cholerton, B K Park, A D Toft.   

Abstract

From clinical observation it would appear that hyperthyroid patients are particularly sensitive to the anticoagulant effects of warfarin. A study was made of clotting factors prothrombin (II), VII, procoagulant VIII (VIIIC), IX and X and of prothrombin ratio (PTR) and partial thromboplastin time with kaolin (PTT-K). These parameters and warfarin levels were measured before and following a single dose of warfarin given to five patients when hyperthyroid and again when euthyroid. Hyperthyroidism was associated with lower activity of factor II and a shorter PTT-K. Warfarin produced a greater fall in factors II and VII and a greater increase in PTR and PTT-K in the hyperthyroid state than in the euthyroid state. The enhanced response to warfarin in hyperthyroidism was, however, relatively greater for the PTR than for the PTT-K. In order to produce adequate protection against intravascular thrombosis by a suitable prolongation of the PTT-K, it may be necessary in hyperthyroid patients to extend the PTR beyond the normal therapeutic range.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3704105

Source DB:  PubMed          Journal:  Q J Med        ISSN: 0033-5622


  18 in total

Review 1.  Thyroid disease and the heart.

Authors:  A D Toft; N A Boon
Journal:  Heart       Date:  2000-10       Impact factor: 5.994

2.  Assessment of the Impact of L-Thyroxine Therapy on Bleeding Risk in Patients Receiving Vitamin K Antagonists.

Authors:  Farès Moustafa; Rémi Malhomme; Bruno Pereira; Alain Barres; Jennifer Saint-Denis; Frederic Dutheil; Marie Batisse; Jeannot Schmidt
Journal:  Clin Drug Investig       Date:  2017-10       Impact factor: 2.859

3.  Potentiation of warfarin sodium by amiodarone-induced thyrotoxicosis.

Authors:  K A Woeber; I Warner
Journal:  West J Med       Date:  1999-01

Review 4.  The haematology of hyperthyroidism: abnormalities of erythrocytes, leucocytes, thrombocytes and haemostasis.

Authors:  H C Ford; J M Carter
Journal:  Postgrad Med J       Date:  1988-10       Impact factor: 2.401

Review 5.  Physiological changes due to age. Pharmacodynamic changes of drug action and implications for therapy.

Authors:  P P Lamy
Journal:  Drugs Aging       Date:  1991 Sep-Oct       Impact factor: 3.923

6.  A population-based assessment of the drug interaction between levothyroxine and warfarin.

Authors:  D Pincus; T Gomes; C Hellings; H Zheng; J M Paterson; M M Mamdani; D N Juurlink
Journal:  Clin Pharmacol Ther       Date:  2012-10-24       Impact factor: 6.875

7.  Major Haemorrhage during Vitamin K Antagonist Treatment: The Influence of Thyroid Hormone Levels.

Authors:  Jan Debeij; Suzanne C Cannegieter; Bregje van Zaane; Anton P van Zanten; Frits R Rosendaal; Victor E A Gerdes; Pieter H Reitsma; Olaf M Dekkers
Journal:  Eur Thyroid J       Date:  2014-02-28

Review 8.  Potentially significant drug interactions of class III antiarrhythmic drugs.

Authors:  Weeranuj Yamreudeewong; Michael DeBisschop; Linda G Martin; Dennis L Lower
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

9.  Blood coagulation and fibrinolysis in patients with hyperthyroidism.

Authors:  C Erem; H O Ersoz; S S Karti; K Ukinç; A Hacihasanoglu; O Değer; M Telatar
Journal:  J Endocrinol Invest       Date:  2002-04       Impact factor: 4.256

Review 10.  Thyroid, hemostasis and thrombosis.

Authors:  F Marongiu; C Cauli; S Mariotti
Journal:  J Endocrinol Invest       Date:  2004-12       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.